Onsdag 5 oktober


Dr Mathias Ekman

Titel: Vad krävs det att bli världsledande inom Life science i en digital tidsålder?


Mathias Ekman is Director Digital Platforms and Ecosystems at Microsoft Word Wide Health & Life science Group. His role is to work with key stakeholders at Governments as well as innovative start-ups to accelerate the digital transformation. The goal is together with the partner ecosystem democratize AI and clinical knowledge in order to address some of the hardest challenges in society.


He joined Microsoft in 2014, prio to this he held several leading positions at different consultant companies working with clients in the field of connected vehicle, advanced analytics in the financial sector as well establishing solution for screening of colorectal cancer.


Mathias holds a PhD in Theoretical Physics focusing on large scale computing for solving problems explained by quantum physics.

Torsdag 6 oktober

Prof. Molly M. Stevens
Prof Molly M Stevens FREng FRS is Professor of Biomedical Materials and Regenerative Medicine and the Research Director for Biomedical Material Sciences in the Department of Materials and Bioengineering at Imperial College London.


Prof Stevens’ research balances fundamental science with technological development to address major healthcare challenges. Her work has been instrumental in elucidating bio-material interfaces, and she has a broad portfolio of designer biomaterials for disease diagnostics and regenerative medicine. Her work influences research groups around the world with over 30 major awards for the groups research.


Prof Stevens holds numerous leadership positions including Director of the UK Regenerative Medicine Platform "Smart Acellular Materials" Hub. She is the founder of several companies translating innovations in therapeutics and biosensing.


Title: Designing materials for therapeutics and ultrasensitive biosensing


This talk will provide an overview of our recent developments in bio-instructive, self-assembling and gradient materials for applications in regenerative medicine with focus on establishing translational pipelines to bring our innovations to the clinic [1]. Our group has developed fabrication methods to engineer complex 3D architectures that mimic anisotropic and multiscale tissue structures and generate spatially arranged bioinstructive biochemical cues. I will discuss recent advances in our tunable nanoneedle arrays for multiplexed intracellular biosensing at sub-cellular resolution and modulation of biological processes [2], and will talk about our portfolio of nanoparticle-based sensing probes for diagnosing and monitoring infectious and non-communicable diseases with integration to smartphone technology for mHealth approaches [3,4]. We are also advancing Raman spectroscopy characterisation techniques for high-throughput label-free characterization of single nanoparticles -SPARTAÒ - which is becoming an integral tool for the design of advanced nanotherapeutics [6]. I will explore how these versatile technologies can be applied to transformative biomedical innovations.


[1] J. P. K. Armstrong… M. M. Stevens. “A blueprint for translational regenerative medicine.” Science Translational Medicine. 2020. 12(572): eaaz2253.

[2] C. Chiappini…  M. M. Stevens, E. Tasciotti. “Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization.” Nature Materials. 2015. 14: 532

[3] C. N. Loynachan… M. M. Stevens. “Renal clearable catalytic gold nanoclusters for in vivo disease monitoring.” Nature Nanotechnology. 2019. 14: 883–890.

[4] C. S. Wood, … M. M. Stevens. “Taking connected mobile-health diagnostics of infectious diseases to the field.” Nature. 2019. 566: 467-474.

[5] J. Penders… M. Stevens. “Single particle automated Raman trapping analysis.” Nature Communications. 2018, 9: 4256.